Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10398283 | 0.92 | RCE1 (0.53) | RCE1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6901088 | 0.92 | RCE1 (0.53) | RCE1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL10399486 | 0.91 | RCE1 (0.52) | RCE1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL10399412 | 0.91 | LMNA (0.56) | RCE1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL28107769 | 0.90 | MEN1 (0.61) | RCE1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL14544524 | 0.88 | LPAR1 (0.67) | KMT2AMEN1NPC1RAB9ATDP1 | |
| SCHEMBL7228409 | 0.86 | MEN1 (0.61) | RCE1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2117209 | 0.86 | LMNA (0.62) | KMT2AMEN1NPC1RAB9ATDP1 | |
| SCHEMBL678725 | 0.85 | L3MBTL1 (0.54) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL3662061 | 0.85 | LMNA (0.58) | KMT2AMEN1LMNAALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | claimed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | claimed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | RCE1 141/4885KMT2A 1208/4885MEN1 4741/4885 |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | CYP2A6, CYP2B6, CYP2A13 | RCE1 514/4885KMT2A 1134/4885MEN1 4794/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | RCE1 188/4885KMT2A 1330/4885MEN1 4837/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | RCE1 188/4885KMT2A 1330/4885MEN1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.